A phase 1/2 study of CD19 directed CAR-NK cells in 11 patients with B-NHL (5 CLL, 2 DLBCL, 3 tFL and 1 FL) attempted to address this problem by providing a further Il-15 signal within the product. This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.